Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs.

Pamela E Scott,Ellis F Unger,Marjorie R Jenkins,Mary Ross Southworth, Tzu-Yun McDowell,Ruth J Geller, Merina Elahi,Robert J Temple,Janet Woodcock

Journal of the American College of Cardiology（2018）

引用 239|浏览16

暂无评分

摘要

Women were well represented in trials of drugs for hypertension and atrial fibrillation, and overrepresented for pulmonary arterial hypertension. Representation of women fell below a PPR of 0.8 for trials in heart failure, coronary artery disease, and acute coronary syndrome. Minimal gender differences in drug efficacy and safety profiles were observed.

查看译文

关键词

cardiovascular diseases/therapy,clinical trials,drug efficacy,drug safety,Food and Drug Administration,women’s health

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要